As a result, next-generation sequencing (NGS) is a key tool for detecting somatic mutations in BRCA1/2 to identify metastatic prostate cancer patients who could benefit from PARP inhibitor therapies [14,15]. The gene discussed is BRCA1; the disease is Familial prostate cancer.